Skip to main content
TipRanks
Go Ultimate75% OFF

Aprogen Biologics (003060) Stock Statistics & Valuation Metrics

Total Valuation

Aprogen Biologics has a market cap or net worth of KRW 35.43B. The enterprise value is KRW 305.99B.

Market Cap
KRW 35.43B
Enterprise Value
KRW 305.99B

Share Statistics

Aprogen Biologics has 30,079,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
30,079,500
Owned by Insiders
―
Owned by Institutions
0.02%

Financial Efficiency

Aprogen Biologics’s return on equity (ROE) is -0.82 and return on invested capital (ROIC) is -23.13%.

Return on Equity (ROE)
-0.82
Return on Assets (ROA)
-0.29
Return on Invested Capital (ROIC)
-23.13%
Return on Capital Employed (ROCE)
-0.34
Revenue Per Employee
194.23M
Profits Per Employee
-451.81M
Employee Count
377
Asset Turnover
0.12
Inventory Turnover
1.97

Valuation Ratios

The current PE Ratio of Aprogen Biologics is -0.23. Aprogen Biologics’s PEG ratio is -0.00.

PE Ratio
-0.23
PS Ratio
0.18
PB Ratio
0.10
Price to FCF
-0.48
Price to Operating Cash Flow
-0.66
PEG Ratio
-0.00

Income Statement

In the last 12 months, Aprogen Biologics had revenue of 73.23B and earned -170.33B in profits. Earnings per share was -12923.54.

Revenue
73.23B
Gross Profit
-28.42B
Operating Income
-122.89B
Pretax Income
-169.38B
Net Income
-170.33B
EBITDA
-103.70B
Earnings Per Share (EPS)
-12923.54

Cash Flow

In the last 12 months, operating cash flow was -32.32B and capital expenditures -3.83B, giving a free cash flow of -36.15B billion.

Operating Cash Flow
-32.32B
Free Cash Flow
-36.15B
Free Cash Flow per Share
-1958.40

Dividends & Yields

Aprogen Biologics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-207.90%
Earnings Yield
-378.77%

Stock Price Statistics

Beta
0.07
52-Week Price Change
-86.35%
50-Day Moving Average
1473.90
200-Day Moving Average
2802.35
Relative Strength Index (RSI)
23.72
Average Volume (3m)
311.36K

Important Dates

Aprogen Biologics upcoming earnings date is Mar 18, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 13, 2026
Next Earnings Date
Mar 18, 2027
Ex-Dividend Date
―

Financial Position

Aprogen Biologics as a current ratio of 0.67, with Debt / Equity ratio of 108.46%

Current Ratio
0.67
Quick Ratio
0.45
Debt to Market Cap
2.02
Net Debt to EBITDA
-1.94
Interest Coverage Ratio
-11.49

Taxes

In the past 12 months, Aprogen Biologics has paid -1.08B in taxes.

Income Tax
-1.08B
Effective Tax Rate
0.01

Enterprise Valuation

Aprogen Biologics EV to EBITDA ratio is -10.05, with an EV/FCF ratio of -6.71.

EV to Sales
2.45
EV to EBITDA
-10.05
EV to Free Cash Flow
-6.71
EV to Operating Cash Flow
-7.28

Balance Sheet

Aprogen Biologics has KRW 22.70B in cash and marketable securities with KRW 210.84B in debt, giving a net cash position of -KRW 188.14B billion.

Cash & Marketable Securities
KRW 22.70B
Total Debt
KRW 210.84B
Net Cash
-KRW 188.14B
Net Cash Per Share
-KRW 6,254.74
Tangible Book Value Per Share
KRW 19.14K

Margins

Gross margin is -23.69%, with operating margin of -140.72%, and net profit margin of -83.47%.

Gross Margin
-23.69%
Operating Margin
-140.72%
Pretax Margin
-74.01%
Net Profit Margin
-83.47%
EBITDA Margin
-24.41%
EBIT Margin
-130.91%

Analyst Forecast

The average price target for Aprogen Biologics is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
17.80%
EPS Growth Forecast
64.55%

Scores

Smart Score
―
AI Score
40